On October 1, 2021 Window Therapeutics, Inc. (Window), a Massachusetts-based therapeutics company, reported a foundational partnership and seed funding in collaboration with the National Foundation for Cancer Research (NFCR) through its AIM-HI Accelerator Fund (AIM-HI) biotechnology innovation award program (Press release, National Foundation for Cancer Research, JAN 10, 2021, View Source [SID1234609539]). Terms of the seed-funding round were not disclosed.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Founded in 2020, Window is creating next-generation cancer therapeutics designed to overcome limited efficacy and prohibitive toxicity which often confound successful drug development and as well as favorable patient outcomes. The company’s revolutionary technology platform derives from research that began over ten years ago by Dr. Jeremiah Johnson at the Massachusetts Institute of Technology (MIT). Window’s Bottle-brush Analogue Macromolecule (BAM) platform modifies the therapeutic window of small molecule, immune-based, and combination drug treatments to maximize efficacy specifically within disease sites. AIM-HI identified Window, its technology, and lead drug programs as possessing significant potential for transforming cancer drug development and advancing promising targeted drugs and immunotherapeutic to the clinic in an accelerated manner. AIM-HI’s lead role in the seed-funding of Window is intended to catalyze the progression of its lead candidates to the clinic, based on BAM technology that alleviates the pharmacokinetics, bioavailability, and off-target effects that so often lead to drug candidate failure in clinical trials.
"The Window Therapeutics’ approach embodies our passion to urgently address the limitations of current cancer therapies," said Sujuan Ba, Ph.D., co-Founder of AIM-HI and Chief Executive Officer of NFCR. "Our support for translating promising research from academia to the clinic by selectively identifying and nurturing early-stage companies accelerates treatment breakthroughs for cancer patients worldwide."
"AIM-HI’s support in creating a path forward to the clinic for our novel, bottle-brush macromolecule-based drug programs to benefit cancer patients is truly transformational," remarked Jeremiah Johnson, Ph.D., Window Therapeutics co-Founder, and Scientific Advisor. "Following a decade of progressive development to reconfigure drug therapeutic windows, we aspire to help clinicians and patients achieve and sustain successful outcomes."